JP2023539370A5 - - Google Patents
Info
- Publication number
- JP2023539370A5 JP2023539370A5 JP2023514418A JP2023514418A JP2023539370A5 JP 2023539370 A5 JP2023539370 A5 JP 2023539370A5 JP 2023514418 A JP2023514418 A JP 2023514418A JP 2023514418 A JP2023514418 A JP 2023514418A JP 2023539370 A5 JP2023539370 A5 JP 2023539370A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- cells
- fragment
- item
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063073910P | 2020-09-02 | 2020-09-02 | |
| US63/073,910 | 2020-09-02 | ||
| US202163147473P | 2021-02-09 | 2021-02-09 | |
| US63/147,473 | 2021-02-09 | ||
| PCT/US2021/048771 WO2022051437A2 (en) | 2020-09-02 | 2021-09-01 | Methods to stimulate hla-agnostic immune responses to proteins using nucleated cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023539370A JP2023539370A (ja) | 2023-09-13 |
| JP2023539370A5 true JP2023539370A5 (enExample) | 2024-09-10 |
Family
ID=78212608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023514418A Pending JP2023539370A (ja) | 2020-09-02 | 2021-09-01 | 有核細胞を使用してタンパク質に対するｈｌａ非依存的な免疫応答を刺激する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230263879A1 (enExample) |
| EP (1) | EP4208192A2 (enExample) |
| JP (1) | JP2023539370A (enExample) |
| KR (1) | KR20230079066A (enExample) |
| CN (1) | CN116406283A (enExample) |
| TW (1) | TW202227125A (enExample) |
| WO (1) | WO2022051437A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4271711A1 (en) * | 2020-12-29 | 2023-11-08 | SQZ Biotechnologies Company | Methods for treating cancers with modified pbmcs |
| EP4405487A4 (en) * | 2021-09-26 | 2025-12-03 | Wuxi Biologics Ireland Ltd | IL-2 VARIANTS AND THEIR FUSING PROTEINS |
| WO2025140126A1 (en) * | 2023-12-25 | 2025-07-03 | Everest Medicines (China) Co., Ltd. | Therapeutic ly6k mrna vaccine for cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20170074235A (ko) * | 2014-10-31 | 2017-06-29 | 메사추세츠 인스티튜트 오브 테크놀로지 | 면역 세포로의 생체분자의 전달 |
| AU2019234549B2 (en) * | 2018-03-12 | 2026-02-12 | Sqz Biotechnologies Company | Methods for treating HPV-associated diseases |
| MX2021006393A (es) * | 2018-11-29 | 2021-10-13 | Univ Texas | Metodos para expansion ex vivo de celulas exterminadoras naturales y uso de las mismas. |
| CA3131701A1 (en) * | 2019-02-28 | 2020-09-03 | Sqz Biotechnologies Company | Delivery of biomolecules to pbmcs to modify an immune response |
| JP7820663B1 (ja) * | 2024-09-25 | 2026-02-26 | ダイキン工業株式会社 | 設備管理装置、プログラム、設備管理システム |
-
2021
- 2021-09-01 CN CN202180071943.1A patent/CN116406283A/zh active Pending
- 2021-09-01 KR KR1020237010604A patent/KR20230079066A/ko active Pending
- 2021-09-01 WO PCT/US2021/048771 patent/WO2022051437A2/en not_active Ceased
- 2021-09-01 JP JP2023514418A patent/JP2023539370A/ja active Pending
- 2021-09-01 EP EP21794031.1A patent/EP4208192A2/en active Pending
- 2021-09-01 US US18/043,613 patent/US20230263879A1/en active Pending
- 2021-09-02 TW TW110132703A patent/TW202227125A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023539370A5 (enExample) | ||
| JP6109800B2 (ja) | 最大限のｇａｇ及びｎｅｆを樹状細胞に対して標的化することに基づくｈｉｖワクチン | |
| JP2021517813A5 (enExample) | ||
| Matthews et al. | Potent induction of antibody-secreting B cells by human dermal-derived CD14+ dendritic cells triggered by dual TLR ligation | |
| TW201300418A (zh) | 用於抗ｃ型肝炎病毒免疫之組合物及方法 | |
| Tellam et al. | mRNA Structural constraints on EBNA1 synthesis impact on in vivo antigen presentation and early priming of CD8+ T cells | |
| US20230263879A1 (en) | Methods to stimulate hla-agnostic immune responses to proteins using nucleated cells | |
| Melchers et al. | A stabilized HIV-1 envelope glycoprotein trimer fused to CD40 ligand targets and activates dendritic cells | |
| CN112218655A (zh) | 以人工混合t辅助细胞表位以有限度的t细胞炎性反应促进目标抗体的生产 | |
| CA2625506C (en) | Immuno-stimulant combination for prophylaxis and treatment of hepatitis c | |
| US20230181712A1 (en) | Combination therapy with modified pbmcs and an immunoconjugate | |
| JP2023549030A (ja) | ヘルペスウイルスポリエピトープワクチン | |
| Lasaro et al. | Potentiating vaccine immunogenicity by manipulating the HVEM/BTLA pathway and other co-stimulatory and co-inhibitory signals of the immune system | |
| WO2022089233A1 (zh) | 重组刺突蛋白及其制备方法和用途 | |
| Bettini | Untangling the Adjuvanticity of mRNA Vaccines: Nucleoside-Modified mRNA and Lipid Nanoparticles Cooperate to Drive T Follicular Helper Cell Responses | |
| KR20060122623A (ko) | 인간 및 비근교계 동물에서 세포독성 ｔ 임파구 활성을효과적으로 측정하는 방법 | |
| AU2012202953B2 (en) | HIV vaccine based on targeting maximized Gag and Nef to dendritic cells | |
| Du et al. | The mechanism of immunopotentiator CVC1302 in promoting long-term humoral immune responses in mice. | |
| RU2022132009A (ru) | Комбинированная терапия модифицированными мнпк и иммуноконъюгатом | |
| HK40083361A (en) | Combination therapy with modified pbmcs and an immunoconjugate | |
| CN116897163A (zh) | 包含IL15蛋白、IL15Rα蛋白、Fc域及IL2蛋白的融合蛋白及其用途 | |
| Suarez-Ramirez | Changing antigen specificity during the CD8 recall response to secondary influenza virus infection | |
| Wieland | Stress protein complexed multidomain vaccines identify subdominant CD8 T-cells with enhanced anti-viral activity. | |
| Melchers et al. | Protein engineering of a stabilized HIV-1 envelope glycoprotein trimer fused to CD40 ligand that activates dendritic cells |